Publicacions en col·laboració amb investigadors/es de Hospital Universitario Son Espases (25)

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

2023

  1. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 8, pp. 2486-2500

  2. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

2022

  1. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence

    European Journal of Internal Medicine, Vol. 100, pp. 33-45

2021

  1. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  2. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  3. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

2020

  1. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750

  2. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

    PloS one, Vol. 15, Núm. 7, pp. e0235848

2019

  1. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer

    Thrombosis and Haemostasis, Vol. 119, Núm. 11, pp. 1849-1859

  2. Quality of life, coping, and psychological and physical symptoms after surgery for non-metastatic digestive tract cancer

    Surgical Oncology, Vol. 31, pp. 26-32

  3. Risk of malnutrition and emotional distress as factors affecting health-related quality of life in patients with resected cancer

    Clinical and Translational Oncology, Vol. 21, Núm. 5, pp. 687-691

2018

  1. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry

    Gastric Cancer, Vol. 21, Núm. 1, pp. 96-105

  2. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  3. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis

    Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264

  4. Factors associated with anxiety and depression in cancer patients prior to initiating adjuvant therapy

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1408-1415

  5. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry

    European Journal of Surgical Oncology, Vol. 44, Núm. 8, pp. 1191-1198

  6. The relationship between physician and cancer patient when initiating adjuvant treatment and its association with sociodemographic and clinical variables

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1392-1399

2017

  1. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: Real-world data from the AGAMENON National Cancer Registry

    British Journal of Cancer, Vol. 117, Núm. 6, pp. 775-782

  2. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: A multicenter prospective study in the era of trastuzumab

    British Journal of Cancer, Vol. 116, Núm. 12, pp. 1526-1535